An update and overview of the literature on late inflammatory reactions (LIRs) in soft tissue fillers after SARS-CoV-2 infection and vaccination

IF 0.6 Q4 SURGERY

European Journal of Plastic Surgery Pub Date : 2023-09-16 DOI:10.1007/s00238-023-02121-w

Yara Bachour

{"title":"An update and overview of the literature on late inflammatory reactions (LIRs) in soft tissue fillers after SARS-CoV-2 infection and vaccination","authors":"Yara Bachour","doi":"10.1007/s00238-023-02121-w","DOIUrl":null,"url":null,"abstract":"Abstract Introduction Soft tissue fillers are widely used and are commonly considered to be safe. Nonetheless, adverse events such as late inflammatory reactions (LIRs) are reported for every type of filler. As of the start of the COVID-19 pandemic, LIRs have been reported after SARS-CoV infection or vaccination. In the past, we reviewed these adverse events; however, since then, we faced a wave with the Omicron, and the vaccination programs continued with booster vaccines. We therefore aimed to perform an up-to-date review of the literature on LIRs after COVID-19 infection and vaccination with additional learned lessons from this pandemic. Material and methods We performed a systematic review on soft tissue filler-related LIRs after SARS-CoV-2 infection or vaccination in line with the PRISMA guidelines. Eligible studies were searched in the database PubMed from 1 August 2021 until 1 June 2023. Data on patient characteristics, filler characteristics, clinical findings, and treatment options were retrieved. Results A total of 14 papers with in total 52 patients were reported, of which 16 had adverse events after a SARS-CoV-2 infection and 36 after SARS-CoV-2 vaccination. In most cases, it concerned females who had their (mostly temporary) fillers for cosmetic purposes. Symptoms were reported in a matter of hours up to weeks after SARS-CoV-2 vaccination (22 Pfizer, 7 Moderna, 3 AstraZeneca, 3 Sputnik V, and one after Siophram), mostly after the first or second dose but sporadically after a third dose. Most patients were treated in a conservative manner. Discussion LIRs continue to be reported after SARS-CoV-2 infection and vaccination and are currently also reported for non-mRNA vaccines, for non-temporary fillers, and also after a third dose of the vaccine. Although there are more and more papers on this matter, they remain minor and self-limiting. We therefore still advise patients with soft tissue fillers to remain participated in vaccination programs when needed. Level of evidence: Not gradable.","PeriodicalId":12054,"journal":{"name":"European Journal of Plastic Surgery","volume":"32 1","pages":"0"},"PeriodicalIF":0.6000,"publicationDate":"2023-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Plastic Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00238-023-02121-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract Introduction Soft tissue fillers are widely used and are commonly considered to be safe. Nonetheless, adverse events such as late inflammatory reactions (LIRs) are reported for every type of filler. As of the start of the COVID-19 pandemic, LIRs have been reported after SARS-CoV infection or vaccination. In the past, we reviewed these adverse events; however, since then, we faced a wave with the Omicron, and the vaccination programs continued with booster vaccines. We therefore aimed to perform an up-to-date review of the literature on LIRs after COVID-19 infection and vaccination with additional learned lessons from this pandemic. Material and methods We performed a systematic review on soft tissue filler-related LIRs after SARS-CoV-2 infection or vaccination in line with the PRISMA guidelines. Eligible studies were searched in the database PubMed from 1 August 2021 until 1 June 2023. Data on patient characteristics, filler characteristics, clinical findings, and treatment options were retrieved. Results A total of 14 papers with in total 52 patients were reported, of which 16 had adverse events after a SARS-CoV-2 infection and 36 after SARS-CoV-2 vaccination. In most cases, it concerned females who had their (mostly temporary) fillers for cosmetic purposes. Symptoms were reported in a matter of hours up to weeks after SARS-CoV-2 vaccination (22 Pfizer, 7 Moderna, 3 AstraZeneca, 3 Sputnik V, and one after Siophram), mostly after the first or second dose but sporadically after a third dose. Most patients were treated in a conservative manner. Discussion LIRs continue to be reported after SARS-CoV-2 infection and vaccination and are currently also reported for non-mRNA vaccines, for non-temporary fillers, and also after a third dose of the vaccine. Although there are more and more papers on this matter, they remain minor and self-limiting. We therefore still advise patients with soft tissue fillers to remain participated in vaccination programs when needed. Level of evidence: Not gradable.

查看原文本刊更多论文

关于SARS-CoV-2感染和疫苗接种后软组织填充物晚期炎症反应(LIRs)的文献更新和综述

摘要:软组织填充物被广泛使用，通常被认为是安全的。然而，不良事件，如晚期炎症反应(LIRs)的报道，每一种类型的填充物。自COVID-19大流行开始以来，在SARS-CoV感染或接种疫苗后报告了lir。在过去，我们回顾了这些不良事件;然而，从那时起，我们面临着欧米克隆的浪潮，疫苗接种计划继续使用加强疫苗。因此，我们旨在对COVID-19感染和疫苗接种后lir的文献进行最新综述，并从此次大流行中吸取更多经验教训。材料和方法我们按照PRISMA指南对SARS-CoV-2感染或接种疫苗后软组织填充物相关的lir进行了系统回顾。从2021年8月1日至2023年6月1日在PubMed数据库中检索了符合条件的研究。检索了患者特征、填充物特征、临床表现和治疗方案的数据。结果共报告文献14篇，患者52例，其中感染SARS-CoV-2后发生不良事件16例，接种后发生不良事件36例。在大多数情况下，它涉及的是出于美容目的而使用(大多是临时的)填充物的女性。在SARS-CoV-2疫苗接种后数小时至数周内报告症状(22例辉瑞、7例Moderna、3例阿斯利康、3例Sputnik V和1例Siophram)，主要在第一剂或第二剂后，但偶尔在第三剂后。多数患者采用保守治疗。在SARS-CoV-2感染和疫苗接种后继续报告lir，目前也报告了非mrna疫苗、非临时填充物以及第三剂疫苗后的lir。虽然关于这个问题的论文越来越多，但它们仍然是次要的和自我限制的。因此，我们仍然建议使用软组织填充物的患者在需要时继续参与疫苗接种计划。证据等级:不可分级。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Plastic Surgery SURGERY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： Europe has always been an area of dynamic development in plastic surgery. Its great strength has been the lack of uniformity of this development due to differing cultures, different traditions, and differing medical and surgical philosophies. Over the recent years, these changes have been even more striking and rapid. The European Journal of Plastic Surgery creates a focal point for the input of new advances in clinical techniques and in research. It thus becomes an educational vehicle. In addition to this, the journal provides information on what is going on elsewhere in the world, and it is also willing to accept contributions from outside of Europe. Fields of interest include general plastic and reconstructive surgery, head and neck surgery, aesthetic and craniofacial surgery, hand surgery, microsurgery, treatment of bones, trauma, burn management and basic research related to all aspects of plastic surgery.Submitted articles are first evaluated by the Editor in Chief and if judged appropriate, are peer-reviewed by at least two selected experts. Reviewers may be plastic surgeons or other surgical/ medical specialists with expertise in specific areas of research. Manuscripts provisionally accepted for publication may be returned to the author for corrections or clarifications, in response to suggestions by the Editorial Board or external reviewers, prior to final acceptance. Online submission and peer review for rapid online publication are offered through the Editorial Manager System. The system creates a PDF version of the submitted article for peer review, revision and proofing. All correspondence, including the request for revisions and final decision, is managed by e-mail. Authors are guided step by step through the full process and are kept up to date on the article’s progress at every stage. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.Reports of animal experiments must state that the ''Principles of laboratory animal care'' (NIH publication No. 86-23, revised in 1985) were followed, as well as specific national laws (e.g. the current version of the German Law on the Protection of Animals) where applicable.Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full. Authors are also required to disclose any relationships with public or private commercial or noncommercial entities, any institutional affiliations, or any personal associations that might pose a conflict of interest.The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfill the above-mentioned requirements.